|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/16/21 Bioforce Nanosciences Holdin… Inc 10-K 12/31/20 32:1.3M Yes International/FA |
Document/Exhibit Description Pages Size
1: 10-K Year End Report Dec. 31, 2020 HTML 176K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 13K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 13K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 10K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 10K
12: R1 Document and Entity Information HTML 49K
13: R2 Consolidated Balance Sheets HTML 62K
14: R3 Consolidated Balance Sheets (Parenthetical) HTML 20K
15: R4 Consolidated Statements of Operations HTML 44K
16: R5 Consolidated Statements of Cash Flows HTML 66K
17: R6 Statements of Changes in Stockholders' (Deficit) HTML 43K
Equity
18: R7 Organization & Description of Business HTML 15K
19: R8 Summary of Significant Accounting Policies HTML 18K
20: R9 Recently Issued Accounting Standards HTML 14K
21: R10 Going Concern HTML 14K
22: R11 Related Party Transactions HTML 15K
23: R12 Stock HTML 16K
24: R13 Risks and Uncertainties HTML 15K
25: R14 Summary of Significant Accounting Policies HTML 37K
(Policies)
26: R15 Organization & Description of Business (Details) HTML 15K
27: R16 Related Party Transactions (Details) HTML 16K
28: R17 Stock (Details) HTML 47K
29: R18 Risks and Uncertainties (Details) HTML 21K
31: XML IDEA XML File -- Filing Summary XML 46K
30: EXCEL IDEA Workbook of Financial Reports XLSX 25K
6: EX-101.INS XBRL Instance -- bfnh-20201231 XML 167K
8: EX-101.CAL XBRL Calculations -- bfnh-20201231_cal XML 71K
9: EX-101.DEF XBRL Definitions -- bfnh-20201231_def XML 95K
10: EX-101.LAB XBRL Labels -- bfnh-20201231_lab XML 306K
11: EX-101.PRE XBRL Presentations -- bfnh-20201231_pre XML 223K
7: EX-101.SCH XBRL Schema -- bfnh-20201231 XSD 54K
32: ZIP XBRL Zipped Folder -- 0001091818-21-000016-xbrl Zip 32K
Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the accompanying Annual Report on Form 10-K, of BioForce Nanosciences Holdings, Inc. for the fiscal year ending December 31, 2020, I, Richard Kaiser, Acting Chief Financial Officer and Principal Accounting Officer of BioForce Nanosciences Holdings, Inc.., hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:
1. Such Annual Report on Form 10-K, for the fiscal year ending December 31, 2020, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in such Annual Report on Form 10-K, for the fiscal year ending December 31, 2020, fairly presents, in all material respects, the financial condition and results of operations of BioForce Nanosciences Holdings, Inc..
Date: February 16, 2020
/s/ Richard Kaiser
Richard Kaiser, Chief Financial Officer and Principal Accounting Officer of BioForce Nanosciences Holdings, Inc.
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 2/16/21 | None on these Dates | ||
| For Period end: | 12/31/20 | |||
| 2/16/20 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/22/20 Bioforce Nanosciences Holdin… Inc 10-Q 6/30/20 41:1.2M Yes International/FA 5/04/20 Bioforce Nanosciences Holdin… Inc 10-Q 3/31/20 43:1.1M Yes International/FA 12/31/19 Bioforce Nanosciences Holdin… Inc DEFR14C 12/31/19 3:90K Yes International/FA 1/26/18 Bioforce Nanosciences Holdin… Inc 10-12G/A 3:4M Yes International/FA 12/19/17 Bioforce Nanosciences Holdin… Inc 10-12G 4:2.2M Yes International/FA |